Oxford Genetics is a leading synthetic biology company focused on developing technologies to associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.
In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.
In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetual. A spokesperson from Oxford Genetics made the following statement regarding the investment:
This will allow us to continue to exeed regulatory requirements and provide quality assurance for our clients. We will also add more analytical, purification and process development equipment, for instance small scale bioreactors, to enable us to fully support our clients from research up to the point of GMP bioproduction.
On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and Merica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:
This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.